wehewehe
Hana maikaʻi ʻia kā mākou Omeprazole intermediate 2.3.5-Trimethyl-4-nitropyridine-N-oxide e hoʻokō i nā kūlana ʻoihana kiʻekiʻe loa, e hōʻoiaʻiʻo ana i kona maʻemaʻe a me ka pono a hiki ke hoʻohana ʻia i nā ʻano hana kemika a me ka lāʻau lapaʻau.Me kona haku mele a me ka maikaʻi ʻokoʻa, he koho kūpono kēia pūhui no ka poʻe noiʻi, ʻepekema a me nā ʻoihana lāʻau lapaʻau e ʻimi nei i nā kikowaena hilinaʻi, hana kiʻekiʻe no kā lākou papahana.
He hana koʻikoʻi kēia mea waena i ka hana ʻana o ka omeprazole, he lāʻau lapaʻau i hoʻohana nui ʻia e mālama i nā maʻi pili i ka waika e like me ka maʻi gastroesophageal reflux (GERD), peptic ulcer, a me zolin (Guardian-Ellison syndrome).Ma ke ʻano he mea nui i ka synthesis o ka omeprazole, ʻo kā mākou omeprazole intermediate 2.3.5-trimethyl-4-nitropyridine-N-oxide e hoʻomaʻamaʻa i ka hana kūpono a me ke kumu kūʻai o kēia mea nui o nā lāʻau lapaʻau.
E koho iā mākou
Loaʻa iā JDK nā hale hana papa mua a me nā lako hoʻokele maikaʻi, e hōʻoiaʻiʻo ana i ka lako paʻa o nā kikowaena API.Hōʻoia ka hui ʻoihana i ka R&D o ka huahana.E kūʻē i nā mea ʻelua, ke ʻimi nei mākou iā CMO & CDMO ma ka mākeke kūloko a me ka honua.